Clinical Trial Update: Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

View source ↗

Summary

A completed clinical trial evaluating glucose-induced GLP-1 secretion in patients with NAFLD/NASH compared with healthy controls.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Non Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis | Status: COMPLETED